Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Farhad Sedarati"'
Autor:
Hiroshi Handa, June-Won Cheong, Yasushi Onishi, Hiroatsu Iida, Yukio Kobayashi, Hyeoung-Joon Kim, Tzeon-Jye Chiou, Koji Izutsu, Olga Tsukurov, Xiaofei Zhou, Helene Faessel, Ying Yuan, Farhad Sedarati, Douglas V. Faller, Akiko Kimura, Shang-Ju Wu
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We report findings from a phase 1/1b s
Externí odkaz:
https://doaj.org/article/16e57d9cb04a4e2ea784bdfdd8aa57cf
Autor:
Xiaofei Zhou, Sharon Friedlander, Erik Kupperman, Farhad Sedarati, Shingo Kuroda, Zhaowei Hua, Ying Yuan, Yuka Yamamoto, Douglas V. Faller, Kazue Haikawa, Katsuhiko Nakai, Sharon Bowen, Yi Dai, Karthik Venkatakrishnan
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 1069-1081 (2021)
Abstract The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐r
Externí odkaz:
https://doaj.org/article/a8426999b0604c1f851464ce578e755b
Autor:
Jayaprakasam Bolleddula, Hao Chen, Lawrence Cohen, Xiaofei Zhou, Sandeepraj Pusalkar, Allison Berger, Farhad Sedarati, Karthik Venkatakrishnan, Swapan K. Chowdhury
Publikováno v:
Drug Metabolism and Disposition. 50:989-997
Autor:
Yuka Yamamoto, Yi Dai, Katsuhiko Nakai, Farhad Sedarati, Erik Kupperman, Shingo Kuroda, Karthik Venkatakrishnan, Xiaofei Zhou, Zhaowei Hua, Douglas V. Faller, Ying Yuan, Sharon Bowen, Kazue Haikawa, Sharon Friedlander
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 3, Pp 1069-1081 (2021)
Clinical and Translational Science, Vol 14, Iss 3, Pp 1069-1081 (2021)
The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐risk chron
Autor:
Jayaprakasam Bolleddula, Xiaofei Zhou, Douglas V. Faller, Yuexian Li, Swapan Chowdhury, Dan Zhao, Hélène M. Faessel, Farhad Sedarati, Karthik Venkatakrishnan, Zsuzsanna Papai
Publikováno v:
Investigational New Drugs. 39:488-498
SummaryPevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the results
Autor:
Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Lwona Dobler, Tomoko Yanai, Farhad Sedarati, Toshio Shimizu, Kyu-Pyo Kim, Douglas V. Faller, Neeraj Gupta
Publikováno v:
Targeted oncology. 17(1)
Sapanisertib is an oral, highly selective inhibitor of mammalian target of rapamycin complexes 1 and 2. The aim of this study was to assess the safety, tolerability, pharmacokinetics, preliminary efficacy, and to establish the recommended phase 2 dos
Autor:
Hélène M. Faessel, Xiaofei Zhou, Karthik Venkatakrishnan, Douglas V. Faller, Farhad Sedarati, Diane R. Mould
Publikováno v:
British Journal of Clinical Pharmacology
Aims A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK. Methods Data were pooled from 6 clinical studies consisting of 335 patients with solid tumo
Autor:
David Smith, Roberto Pili, Farhad Sedarati, Shadia I. Jalal, Andrés Cervantes, Martin H. Voss, Howard A. Burris, Rachel Neuwirth, Teresa Macarulla, Douglas V. Faller, Michael S. Gordon, Monica M. Mita, Vicky Makker, Igor Puzanov, Ding Wang, A. Enke, Brian I. Rini, Shubham Pant, Manish R. Patel, Yaping Shou
Publikováno v:
Scientia
British Journal of Cancer
British Journal of Cancer
Background This Phase 1 dose-escalation/expansion study assessed safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in advanced solid tumours. Methods Eligible patients received increasing sapanisertib doses on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04304289ca3485f1a4178792263b5785
https://hdl.handle.net/11351/6503
https://hdl.handle.net/11351/6503
Autor:
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-pyo Kim
Publikováno v:
Targeted Oncology. 17:377-377
Autor:
Xiaofei, Zhou, Farhad, Sedarati, Douglas V, Faller, Dan, Zhao, Hélène M, Faessel, Swapan, Chowdhury, Jayaprakasam, Bolleddula, Yuexian, Li, Karthik, Venkatakrishnan, Zsuzsanna, Papai
Publikováno v:
Investigational New Drugs
Summary Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the result